Get the Stockscreener App
0.8369
2.81%
-0.0242
After Hours:
.84
0.0031
+0.37%
Aprea Therapeutics Inc stock is traded at $0.8369, with a volume of 93,038.
It is down -2.81% in the last 24 hours and up +22.53% over the past month.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
See More
Previous Close:
$0.8611
Open:
$0.85
24h Volume:
93,038
Relative Volume:
0.04
Market Cap:
$10.03M
Revenue:
$285.80K
Net Income/Loss:
$-12.60M
P/E Ratio:
-0.4239
EPS:
-1.9743
Net Cash Flow:
$-13.44M
1W Performance:
-7.76%
1M Performance:
+22.53%
6M Performance:
-41.06%
1Y Performance:
-52.18%
1-Day Range:
$0.8067
$0.8608
1-Week Range:
$0.8067
$0.9986
52-Week Range:
$0.548
$2.11
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.8369 | 10.32M | 285.80K | -12.60M | -13.44M | -1.9743 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
CatalYm picks ex-Aprea CEO Christian Schade to chair board - Stock Titan
Aprea Abstract Accepted for ASCO on APR-1051 Phase 1 Study - MyChesCo
Aprea Therapeutics (NASDAQ: APRE) reporting group discloses 9.9% stake - Stock Titan
Two life sciences companies with Doylestown connections raise $119M - MSN
Aprea (APRE): Buy, Sell, or Hold? | Q4 2025: EPS Beats ForecastsEV/EBITDA - Xã Vĩnh Công
Aprea Therapeutics (NASDAQ: APRE) registers 74.35M shares for resale by investors - Stock Titan
Aprea Therapeutics abstract accepted at ASCO meeting in May - Investing.com
Aprea Therapeutics abstract accepted at ASCO meeting in May By Investing.com - Investing.com Canada
Aprea Therapeutics Announces Acceptance of Abstract for Phase 1 Study of WEE1 Inhibitor APR-1051 at ASCO 2026 - Quiver Quantitative
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting - Weekly Voice
Early human data on Aprea cancer drug lands ASCO 2026 poster slot - Stock Titan
Aprea Therapeutics (NASDAQ: APRE) seeks board authority for 1‑for‑3–1‑for‑8 reverse split - Stock Titan
Aprea reports partial response in APR-1051 cancer trial - MSN
Aprea (APRE) Stock: Why It Matters Now (Eye on Rally) 2026-04-18Hedge Fund Inspired Picks - Cổng thông tin điện tử tỉnh Lào Cai
Aprea reports 2025 results, early data for APR-1051 trial - MSN
Zentalis Surges 20% on WEE1 Inhibitor Dose Selection—But Is Aprea the Real Winner in This Space? - Barchart.com
10 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
APRE Forecast, Price Target & Analyst Ratings | APREA THERAPEUTICS INC (NASDAQ:APRE) - ChartMill
APRE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
3 Reasons to Avoid PTLO and 1 Stock to Buy Instead - Barchart.com
Analyst Calls: Is Aprea Therapeutics Inc stock a buy or sell2026 Breakouts & Daily Profit Focused Stock Screening - baoquankhu1.vn
Merger Talk: Is Aprea Therapeutics Inc affected by consumer sentimentWeekly Risk Summary & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
3 Reasons HUBG is Risky and 1 Stock to Buy Instead - Barchart.com
Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051 - Barchart
Aug Macro: How does Aprea Therapeutics Inc perform in inflationary periodsCPI Data & Precise Buy Zone Tips - baoquankhu1.vn
What is the biggest uncertainty for Aprea (APRE) Stock | Price at $0.86, Up 17.17%AI Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai
APRE Breaks Key Resistance—But Bears Still Lurk Below - Bitget
Janus and Tecnoglass Shares Are Soaring, What You Need To Know - Barchart.com
Why Trex (TREX) Stock Is Up Today - Barchart.com
Stryker (SYK): Buy, Sell, or Hold Post Q4 Earnings? - Barchart.com
Simply Good Foods (SMPL) Reports Q1: Everything You Need To Know Ahead Of Earnings - Barchart.com
Aprea Therapeutics, Inc.Common Stock (NQ: APRE - FinancialContent
Squadron reports 1.27M warrant stake in Aprea Therapeutics (NASDAQ: APRE) - Stock Titan
Aprea Reports Partial Response in APR-1051 Cancer Trial - MyChesCo
Why Apple (AAPL) Shares Are Falling Today - Barchart
Former Aprea CEO Christian Schade joins Frazier after Halda sale - Stock Titan
Here's What to Expect From 3M Company's Next Earnings Report - Barchart
APRE PE Ratio & Valuation, Is APRE Overvalued - Intellectia AI
APRE Stock Analysis: Aprea Therapeutics Inc. Common Stock Up 1.65 Pct at 0.72 USD - Cổng thông tin điện tử tỉnh Lào Cai
Stocks in play: CGI Inc. - Barchart.com
APRE SEC FilingsAprea Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Soleus entities and Guy Levy report 1.27M shares in Aprea (NASDAQ: APRE) - Stock Titan
Aprea Therapeutics (APRE) CFO buys pre-funded and common warrants - Stock Titan
Aprea Therapeutics (APRE) director buys pre-funded and common stock warrants - Stock Titan
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement - bitget.com
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline - TipRanks
Weekly Earnings: Is Aprea Therapeutics Inc stock a buy or sell2026 Big Picture & Fast Gain Stock Tips - baoquankhu1.vn
Aprea Therapeutics closes $30 million private placement - Investing.com
Aprea Therapeutics closes $30 million private placement By Investing.com - Investing.com India
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aprea Therapeutics Inc Stock (APRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Jan 30 '26 |
Buy |
0.89 |
5,700 |
5,073 |
33,433 |
| Duey Marc | Director |
Dec 10 '25 |
Buy |
1.17 |
21,459 |
25,000 |
256,155 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Dec 10 '25 |
Buy |
1.17 |
5,000 |
5,825 |
27,733 |
0.29%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):